Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its Amplatzer Piccolo™ Delivery System, which is used with the company's Amplatzer ...

Abbott (NYSE: ABT) received FDA clearance for its Amplatzer Piccolo delivery system for use with the Amplatzer Piccolo ...

The Food and Drug Administration clearance and CE mark position Abbott to sell its Amplatzer Piccolo Delivery System in the U ...

- First-of-its-kind steerable delivery system designed for left atrial appendage (LAA) occluder to seal the LAA in people who are at increased risk of stroke due to atrial fibrillation - New delivery ...

Tyler Ramsey's mother saw other children lose their breath when they played basketball, so she thought her son's condition was normal. Sarah Simon's parents never had much endurance, so they didn't ...

Abbott has received a new, broad approval from the FDA for its tiny heart plug implant to help cut down the risk of stroke among people with atrial fibrillation, the most common cardiac arrhythmia.

PARIS, France—Left atrial appendage (LAA) occlusion with the Amplatzer Amulet (Abbott) reduces the risk of ischemic stroke in real-world use through 2 years, for the most part without the need for ...

The Amplatzer Piccolo Occluder received FDA approval and CE Mark in 2019. "We designed the Amplatzer Piccolo Delivery System based on feedback from leading physicians across the world to make PDA ...

First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery system enables precise ...